SCHEMBL5537191

SCHEMBL5537191

C=C(C)CCCn1c(=O)oc2ccccc21

nearest known ligand 0.68

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.68
NPSR1 Q6W5P4 2/20 0.68
TSHR P16473 3/20 0.60
USP2 O75604 1/20 0.60
HPGD P15428 1/20 0.60
SMN1; SMN2 Q16637 2/20 0.59
MAPK1 P28482 2/20 0.59
RAB9A P51151 1/20 0.57
MAPT P10636 1/20 0.57
HSD17B10 Q99714 1/20 0.57
LMNA P02545 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5548457 0.96 ALDH1A1 (0.70) ALDH1A1NPSR1TSHRUSP2HPGD
SCHEMBL5547223 0.87 ALDH1A1 (0.69) ALDH1A1NPSR1TSHRUSP2HPGD
SCHEMBL5547215 0.83 ALDH1A1 (0.72) ALDH1A1NPSR1TSHRUSP2HPGD
SCHEMBL5542532 0.82 HPGD (0.65) ALDH1A1NPSR1TSHRUSP2HPGD
SCHEMBL23182640 0.81 MAPK1 (0.73) ALDH1A1NPSR1TSHRUSP2HPGD
SCHEMBL10284153 0.80 ALDH1A1 (0.78) ALDH1A1NPSR1TSHRUSP2HPGD
SCHEMBL5538352 0.80 ALDH1A1 (0.78) ALDH1A1NPSR1TSHRUSP2HPGD
SCHEMBL27363651 0.80 ALDH1A1 (0.78) ALDH1A1NPSR1TSHRUSP2HPGD
SCHEMBL5503439 0.79 ALDH1A1 (0.81) ALDH1A1NPSR1TSHRUSP2HPGD
SCHEMBL5544569 0.79 ALDH1A1 (0.81) ALDH1A1NPSR1TSHRUSP2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885NPSR1 747/4885TSHR 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.